New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:40 EDTBAYRY, AMGNEMA backs expanded indication for Nexavar for thyroid cancer
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Nexavar. Nexavar is currently indicated for the treatment of patients with hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. The CHMP has now recommended an extension to the indication to include the treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine. Nexavar is marketed by Bayer (BAYRY) and Amgen's (AMGN) Onyx Pharmaceuticals.
News For AMGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
14:42 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 30, 2015
09:02 EDTAMGNAmgen says FDA grants priority review for Kyprolis sNDA
Subscribe for More Information
March 27, 2015
15:40 EDTBAYRYPanasonic Healthcare may bid for Bayer's blood glucose meter unit, Nikkei says
Subscribe for More Information
March 26, 2015
11:13 EDTBAYRYBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:04 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:45 EDTAMGNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
05:31 EDTBAYRYBayer downgraded to Neutral from Buy at UBS
Subscribe for More Information
March 25, 2015
07:17 EDTBAYRYSociety for Reproductive Investigation to hold scientific meeting
62nd Annual Scientific Meeting: SRI 2015 is being held in San Francisco on March 25-28.
March 24, 2015
09:10 EDTAMGNDako announces collaboration agreement with Amgen
Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.
March 23, 2015
12:10 EDTAMGNTeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTAMGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:41 EDTBAYRY, AMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use